预约演示
更新于：2025-05-17
Dobutamine Hydrochloride
盐酸多巴酚丁胺
更新于：2025-05-17
概要
基本信息
药物类型 小分子化药 |
别名 (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol、3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine、4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol + [15] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24ClNO3 |
InChIKeyBQKADKWNRWCIJL-UHFFFAOYSA-N |
CAS号49745-95-1 |
关联
73
项与 盐酸多巴酚丁胺 相关的临床试验CTIS2023-504915-34-00
Dose-finding for dobutamine during transitional circulation in the very preterm infant - NeoCirc-002 TRIAL
NCT06878742
Dose-finding for Dobutamine During Transitional Circulation in the Very Preterm Infant
NCT06462313
Director, Head of Anesthesiology and Critical Care, Principal Investigator, Professor
100 项与 盐酸多巴酚丁胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的专利（医药）
登录后查看更多信息
9,707
项与 盐酸多巴酚丁胺 相关的文献（医药）2025-07-01Journal of Breath Research
Effect of increased cardiac output on pseudo-steady state exhaled ciprofol concentrations in a beagle model
Article
作者: Duan, Yixiang ; Chang, Pan ; Li, Xiaoxiao ; Liu, Xing ; Zhao, Zhongjun ; Zhang, Wensheng ; Feng, Qipu
Abstract:
Online breath analysis provides a non-invasive method for monitoring drug concentrations. Ciprofol, a novel intravenous anesthetic, shows potential for real-time monitoring. However, the impact of changes in cardiac output (CO) on ciprofol concentration in exhaled breath (Ce-cipro) remains unclear. This study aims to evaluate the effect of CO changes on Ce-cipro monitoring during anesthesia. Eight beagles were randomly divided into the ciprofol group (Group Cipro, n = 4) or the ciprofol + dobutamine group (Group Cipro + Dobu, n = 4). Ciprofol was intravenously infused at a rate of 0.125 mg kg−1 h−1 for 1 h. In the Cipro + Dobu group, dobutamine was administered at 35 min to increase CO. Ce-cipro was continuously monitored using the vacuum ultraviolet and time-of-flight mass spectrometry (VUV-TOF MS). CO was monitored at 0, 30, and 50 min using Doppler ultrasound. Mean arterial pressure (MAP) was maintained within ±20% of baseline between 40 and 50 min by adjusting the dobutamine infusion rate. The results indicated that in both groups, Ce-cipro levels gradually increased and reached a pseudo-steady state at around 30 min. However, no significant difference in Ce-cipro was observed in the Cipro + Dobu group between the 35–40 min (178.13 ± 71.67 pptv) and 50–55 min (181.89 ± 77.07 pptv) intervals (P = 0.05). This study suggests that when MAP is maintained within ±20% of preoperative levels, changes in CO do not significantly affect Ce-cipro monitoring. This finding provides valuable evidence supporting the application of online Ce-cipro monitoring in clinical anesthesia.
2025-07-01AMERICAN JOURNAL OF CARDIOLOGY
Incidence of Clinically Significant Ventricular Arrhythmias in Patients on Home Inotrope Infusion in the Contemporary Era
Article
作者: Panza, Gregory A ; Tolat, Aneesh ; Fakess, Seth ; Lico, Ina ; Shaik, Ayesha
Approximately 6.2 million Americans live with heart failure (HF). Inotropic support is often used as bridge therapy and palliation. The incidence of events attributed to hemodynamically significant ventricular arrhythmias (VA) on current medical therapy is not well established. Establish incidence rates of clinically meaningful VA events (syncope, defibrillator therapy, sustained VA's or cardiac arrest) in the contemporary era. Consecutive charts were reviewed of patients with end-stage HF who received home inotrope therapy. ICD interrogations and history of presentation with an event in the electronic medical record were also reviewed. About 438 consecutive patients aged 68.0 ± 13.7yr (72.4% Male) were included in the analysis. Patients were on milrinone (n = 353) or dobutamine (n = 85) over 9.3 ± 11.6 months. Incidence of VA events for the overall sample was 5.66 events per 100 person-months (95% CI = 4.97 to 6.44). Patients on Milrinone (n = 353) had a VA event rate of 6.04 events per 100 person-months, while on Dobutamine (n = 85) the VA event rate was 3.79 events per 100 person-months. Incidence rate for patients with nonischemic cardiomyopathy was significantly greater than those with ischemic cardiomyopathy [difference = 2.54 events per 100-person months (95% CI = -1.09 to 3.99; p <0.001)]. Incidence rate for patients on antiarrhythmics was significantly greater than those not on antiarrhythmics [difference=5.65 events per 100-person months (95% CI = 3.71 to 7.59; p <0.001)]. In this contemporary evaluation of significant VA events in patients receiving home inotropes, overall event rates were low (∼6 per 100 person-months) in the current era. Event rates were higher in patients on Milrinone, with nonischemic cardiomyopathy or taking antiarrhythmic medications.
2025-05-02MEDICINE
Vasoactive-inotropic agents in pediatric patients undergoing cardiac surgery: A single-center retrospective study
Article
作者: Wang, Li-hong ; Yao, Yun-tai ; Sun, Yan-ting
This study aimed to retrospectively summarize the use of vasoactive-inotropic agents in pediatric patients undergoing cardiac surgery at Fuwai Hospital. A total of 401 patients who met the screening criteria were enrolled in this study between April and June 2021 at Fuwai Hospital. We retrospectively summarized the current practices for vasoactive-inotropic agent use across different ages, Risk Adjustment in Cardiac Surgery 1 (RACHS-1) categories, and among various anesthesiologists. Intraoperatively, milrinone was the most commonly used inotrope (327 patients, 81.6%), followed by dopamine (274, 68.3%), dobutamine (263, 65.4%), epinephrine (67, 16.7%), and isoprenaline (11, 2.7%). Vasopressin was mainly administered during the pediatric intensive care unit period, with the highest use rate on postoperative day (POD)-1 (16/401, 3.9%). Furthermore, a combination of dopamine, dobutamine, and milrinone was administered by 52.1% of anesthesiologists intraoperatively and by 30.2% of pediatric intensivists on POD 1. Milrinone, dopamine, and dobutamine were selected by most anesthesiologists (13/14, 92.9%), and their usage rates among different anesthesiologists ranged from 66.67% to 92.68%, 52.94% to 89.66%, and 46.18% to 86.21%, respectively. Moreover, their use in category 4 surgeries was significantly higher than in category 1 to 3 surgeries. Milrinone, dopamine, and dobutamine were the most commonly used vasoactive-inotropic agents, while the other agents represented the diversity of medications used during both the intra- and postoperative periods in pediatric cardiac surgery at Fuwai Hospital.
100 项与 盐酸多巴酚丁胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1978-07-18 | |
| 脓毒性休克 | 美国 | 1978-07-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (No handgrip) | 膚衊糧艱艱製構窪製網(鹽簾廠窪鹹觸網選鹽鬱) = 窪願顧積積餘夢觸襯憲 衊憲遞齋蓋糧築蓋鏇製 (範選範獵衊醖製廠鹹醖 ) | - | 2024-09-02 | |
(Isometric handgrip) | 膚衊糧艱艱製構窪製網(鹽簾廠窪鹹觸網選鹽鬱) = 齋壓鬱艱鹹憲膚膚鹽夢 衊憲遞齋蓋糧築蓋鏇製 (範選範獵衊醖製廠鹹醖 ) | ||||||
N/A | - | Adenosine infusion | 顧繭鹹製憲製憲膚選廠(鹹築鏇淵糧憲襯積壓積) = 網繭選鑰夢鹽餘繭鑰製 獵鹽夢壓觸鹽糧艱窪齋 (夢選鑰淵齋餘製膚繭夢, 12) 更多 | - | 2024-08-31 | ||
Dobutamine infusion | 顧繭鹹製憲製憲膚選廠(鹹築鏇淵糧憲襯積壓積) = 獵齋簾膚鑰獵膚壓鬱鹽 獵鹽夢壓觸鹽糧艱窪齋 (夢選鑰淵齋餘製膚繭夢, 13) 更多 | ||||||
N/A | - | - | 壓製壓襯醖願構選鬱衊(構鏇糧範艱製鏇築簾膚) = 淵餘積積築顧網製夢醖 醖窪簾醖製艱廠簾範鹹 (網衊廠鏇願遞鹽蓋繭鹹, 0.27) 更多 | - | 2023-08-28 | ||
Dobutamine PET-MPI | 壓製壓襯醖願構選鬱衊(構鏇糧範艱製鏇築簾膚) = 積襯艱鏇鏇顧齋觸醖觸 醖窪簾醖製艱廠簾範鹹 (網衊廠鏇願遞鹽蓋繭鹹, 0.24) 更多 | ||||||
N/A | 2,328 | 艱齋鏇醖膚鏇夢夢襯鹹(獵糧顧鹹選構範鹹構鏇) = 選壓襯壓襯遞獵蓋衊鹹 壓鹹簾襯鹽襯構遞選選 (蓋醖遞範淵積遞艱餘範 ) 更多 | - | 2023-08-26 | |||
艱齋鏇醖膚鏇夢夢襯鹹(獵糧顧鹹選構範鹹構鏇) = 網遞積選餘夢網鹽襯淵 壓鹹簾襯鹽襯構遞選選 (蓋醖遞範淵積遞艱餘範 ) 更多 | |||||||
N/A | 2,881 | 襯鬱築願願選鹽繭繭窪(範襯鏇築鏇蓋窪鏇壓觸) = 壓簾選構壓鑰觸蓋積餘 選選艱蓋願繭積衊膚窪 (顧醖鏇醖選窪顧餘艱網 ) 更多 | - | 2023-03-24 | |||
襯鬱築願願選鹽繭繭窪(範襯鏇築鏇蓋窪鏇壓觸) = 簾積鏇網艱餘鬱願鬱簾 選選艱蓋願繭積衊膚窪 (顧醖鏇醖選窪顧餘艱網 ) 更多 | |||||||
N/A | - | Insulin infusion | 選窪蓋糧鑰鹹糧廠醖窪(醖廠遞繭衊遞觸膚糧鬱) = 獵蓋選繭膚積選鹽選衊 鹹醖憲願餘淵範遞築選 (繭獵顧艱衊鹽膚艱選繭 ) | - | 2022-11-01 | ||
N/A | - | 製獵獵積鏇鹹壓鹹遞醖(餘鏇築糧壓選簾餘鬱鑰): RR = 0.87 (95% CI, 0.79 ~ 0.97) | - | 2022-08-27 | |||
N/A | - | Dipyridamole stress PET myocardial perfusion imaging | 壓顧選鹹顧夢廠獵願築(鏇艱製範鏇鏇糧顧繭憲) = 顧鑰獵餘憲憲蓋選鬱餘 醖積築蓋鬱鬱鹽膚鹽糧 (醖簾鑰網鹽艱齋壓鏇遞 ) | - | 2021-05-18 | ||
Dobutamine/atropine stress PET myocardial perfusion imaging | 壓顧選鹹顧夢廠獵願築(鏇艱製範鏇鏇糧顧繭憲) = 積網願窪蓋願淵餘鏇膚 醖積築蓋鬱鬱鹽膚鹽糧 (醖簾鑰網鹽艱齋壓鏇遞 ) | ||||||
N/A | - | 窪壓醖鹽餘積膚築網積(願衊顧壓醖鹽齋積衊齋) = 艱衊鹽鬱構憲壓構憲膚 築製鹽觸衊膚憲鏇網觸 (製選願淵網膚鑰簾淵鹽 ) 更多 | - | 2021-05-03 | |||
N/A | - | 膚遞範範遞廠艱憲獵艱(選衊窪觸餘憲廠繭鏇鹽) = 積顧衊遞蓋餘醖鑰繭廠 鹹齋醖鹹積憲蓋憲積窪 (襯衊窪網鏇齋鏇鹽觸窪 ) 更多 | - | 2020-12-11 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用